Malignant LymphomasDecision Making and Problem Solving

[1]  D. Niederwieser,et al.  Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL). , 2004 .

[2]  M. Cragg,et al.  Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. , 2004, Blood.

[3]  R. Gascoyne,et al.  Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Fisher,et al.  A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. , 2003, Blood.

[5]  M. Cragg,et al.  Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. , 2003, Blood.

[6]  L. Kanz,et al.  CLONAL SELECTION OF CD20‐NEGATIVE NON‐HODGKIN'S LYMPHOMA CELLS AFTER TREATMENT WITH ANTI‐CD20 ANTIBODY RITUXIMAB , 1999, British journal of haematology.

[7]  R. Gressin,et al.  High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. , 2005, Blood.

[8]  L. Gordon,et al.  Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Ghielmini,et al.  Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. , 2004, Blood.

[10]  M. Czuczman,et al.  Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Kinoshita,et al.  CD20-negative relapse in B-cell lymphoma after treatment with Rituximab. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Denardo,et al.  A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. , 2000, Anticancer research.

[13]  J. Hainsworth,et al.  Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Freedman,et al.  B-cell purging in autologous stem-cell transplantation for non-Hodgkin lymphoma. , 2004, The Lancet. Oncology.

[15]  E. Kimby.  Beyond immunochemotherapy: Combinations of rituximab with cytokines interferon-α2a and granulocyte-macrophage colony stimulating factor , 2002 .

[16]  J. Leonard,et al.  Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Kimby,et al.  Chimeric Anti-CD20 Monoclonal Antibody (Rituximab;Mabthera) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma: Final Analysis of a Phase III Randomized Intergroup Clinical Trial. , 2004 .

[18]  S. Horning,et al.  Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. , 1995, Blood.

[19]  P. Zinzani,et al.  Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. , 2005, Haematologica.

[20]  M. Sydes,et al.  High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[22]  M. Hansmann,et al.  Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Vose,et al.  Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Gordon,et al.  Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. , 2004, Blood.

[25]  B. Bonavida,et al.  Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[26]  M. Tesar,et al.  Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells , 2002, Nature Medicine.

[27]  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells , 2000, Cancer immunology, immunotherapy : CII.

[28]  Ruta Bajorunaite,et al.  Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. , 2003, Blood.

[29]  V. Diehl,et al.  Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. , 2004, Blood.

[30]  E. Jaffe,et al.  The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. , 1988, Seminars in hematology.

[31]  L. Gordon,et al.  Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Pileri,et al.  Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  W. Hiddemann,et al.  IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group , 2000, Annals of Hematology.

[34]  W. Hiddemann,et al.  Rituximab maintenance following a rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) , 2005 .

[35]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  E. Noordijk,et al.  Non-Hodgkin's lymphoma in the elderly , 2003, Annals of Hematology.

[37]  D. Maloney,et al.  Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Czuczman,et al.  Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Ghielmini,et al.  The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  M. Boccadoro,et al.  Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Leonard,et al.  Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  H. Tilly,et al.  Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  G. Salles,et al.  Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. , 2001, Blood.

[44]  W. Weng,et al.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  W. Hiddemann,et al.  Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Rossi,et al.  Rituximab Activity Is Potentiated by GM-CSF in Patients with Relapsed, Follicular Lymphoma: Results of a Phase II Study. , 2005 .

[47]  S. Horning,et al.  Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  J. Hainsworth,et al.  Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  L. Gordon,et al.  Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Valeria Grieco,et al.  Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1 , 2003, The Journal of Immunology.

[51]  A. Shamseddine,et al.  Loss of CD20 expression in relapsed lymphomas after rituximab therapy , 2003, European journal of haematology.

[52]  R. Marcus,et al.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.

[53]  A. Cuzzocrea,et al.  Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab , 2003, Bone Marrow Transplantation.

[54]  M. Neuberger,et al.  Mice carrying a CD20 gene disruption , 1998, Immunogenetics.

[55]  J. Vose,et al.  Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  B. Bonavida,et al.  Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention , 2005, Oncogene.

[57]  A. Ganser,et al.  Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  J. Gribben,et al.  Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. , 1999, Blood.

[59]  Hervé Watier,et al.  From the bench to the bedside: ways to improve rituximab efficacy. , 2004, Blood.

[60]  N. Mitsiades,et al.  Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies , 2001, Journal of immunotherapy.

[61]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  A. Pileri,et al.  Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion , 2000 .

[63]  Richard L Wahl,et al.  131I-tositumomab therapy as initial treatment for follicular lymphoma. , 2005, The New England journal of medicine.

[64]  M. Kaminski,et al.  Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. , 2000, Blood.

[65]  R. Bosch-Príncep,et al.  CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature , 2003, Annals of Hematology.

[66]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[67]  J. Hainsworth,et al.  Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  C. Lynch,et al.  Improved survival of follicular lymphoma patients in the United States. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  A. Younes,et al.  Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma. , 2003, Clinical lymphoma.

[70]  J. Byrd,et al.  Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  H. Kantarjian,et al.  Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. , 2003, Blood.

[72]  K. Maclennan,et al.  Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial , 2003, The Lancet.

[73]  L. Gordon,et al.  Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. , 2002, Blood.

[74]  A. Hagenbeek,et al.  HuMax-CD20 Fully Human Monoclonal Antibody in Follicular Lymphoma. First Human Exposure: Early Results of an Ongoing Phase I/II Trial. , 2004 .

[75]  Boris Gorovits,et al.  Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. , 2004, Blood.

[76]  D. Goldenberg,et al.  Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s Lymphoma , 2004, Clinical Cancer Research.

[77]  W. Hiddemann,et al.  Combined immuno-chemotherapy (R-FCM) results in superior remission rates and overall survival in recurrent follicular and mantle cell lymphoma: Follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) , 2005 .

[78]  J. K. Hofmeister,et al.  Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. , 2000, Blood cells, molecules & diseases.

[79]  T. Witzig,et al.  Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. , 2005, Cancer biotherapy & radiopharmaceuticals.